Last year was a big year for the Biosimilar Industry. Sandoz brought the first biosimilar to approval. We got to bear witness to the first “patent-dance”. The World Biosimilar Congress USA (WBC-USA) had its successful inaugural year, bringing together over 300 researchers from academia and pharma in San Diego.
It was also a rough year for the pharmaceutical industry, where politicians and public opinion alike have lambasted the pricing structure we have become accustomed to. With a fraction of the development cost of these biologic drugs, Biosimilars have the opportunity to change all that.
Following the release of the FDA’s purple book, the World Biosimilar Congress USA launched to bring focus to the important and distinct issues facing the biopharmaceutical industry. When it comes to developing and commercializing biosimilars in the United States from the payer or biosimilar manufacturing perspective, WBC is the largest event in North America.
Since last year’s event, the industry has matured, and now the industry waits for the floodgates to open while trying to predict hurdles and challenges that will be faced in an environment with limited regulatory guidance.
That is why for 2017, we are growing the WBC-USA even further to showcase a year’s worth of maturity in a still young marketplace. We will be bringing in:
When it comes to biosimilars, the US isn’t Europe – we need to bring out more of the scientific and regulatory challenges that come with a younger market. So this year, we are doing just that.
Even better, the event is still co-located with Americas Antibody Congress 2017 and the Cell Culture World Congress USA 2017, where researchers will be showcasing nearly 40 hours of new preclinical and clinical data.